Bristol-Myers hits estimates for the quarter but still faces tough going

Facing a generic onslaught next month for its best-selling Plavix, Bristol-Myers Squibb ($BMY) managed to bring in earnings that at least met expectations. The company reported $1.1 billion in net inc…
Read the full story: News